PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsgaucher disease
MeSH D005776 - gaucher disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D013106:Sphingolipidoses
0 Companies
0 Drugs
Success rate
D005776: 
Gaucher disease
19 Companies
6 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaEliglustat Eliglustat  2021-12-27   
Johnson & JohnsonMiglustat Zavesca  2002-11-20   
SanofiEliglustat Cerdelga 2022-04-29 2014-08-19   
Imiglucerase Cerezyme  1994-05-23   
PfizerTaliglucerase alfa Elelyso  2012-05-01   
TakedaVelaglucerase alfa Vpriv  2010-02-26   
Dr Reddys LaboratoriesEliglustat Eliglustat  2022-08-17   
Chartwell PharmaceuticalsMiglustat Miglustat  2022-02-03   
ANI PharmaceuticalsMiglustat Miglustat  2018-04-17   
Aizant Drug Research SolutionsEliglustat Eliglustat  2021-09-08   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
93%
13/14
Phase 2
48%
11/23
Phase 3
83%
15/18
Approved: 10Overall Success rate: 37%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Sanofi
Eliglustat,
Imiglucerase,
Venglustat,
Alglucerase,
Aspartame,
Nepidermin,
Valine
Pfizer
Taliglucerase alfa,
Alglucerase,
Aspartame
Takeda
Velaglucerase alfa,
Alglucerase
Actelion
Miglustat,
Ogt918
Amicus Therapeutics
Miglustat
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use